Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2012

View Archived Issues

TMX-202 shows potential as intravesically administered bladder cancer therapy

Orteronel investigated in nonmetastatic prostate cancer

Updated results presented from the AXIS trial

New VCP inhibitors designed in Japan

Novel metabotropic glutamate mGlu2 receptor antagonists patented

Prous Institute for Biomedical Research reports new multitargeted products

Eli Lilly presents novel products with potential to treat cancer

New 11-beta-HSD1 inhibitors developed at High Point Pharmaceuticals

Auriga identifies novel potential therapeutics for photodermatosis

Selective serotonin transporter radioligand investigated in healthy subjects and patients

Sirona Biochem assesses lead product in model of diabetes

Novartis seeks Afinitor line extensions in Japan

EMA accepts Takeda's MAA for peginesatide

Angiochem and GSK launch new collaboration

Eisai offers overview of third quarter of fiscal 2011

Neuronex enters merger agreement

CSL Behring screens first patient in global rVIII-SingleChain study

European Commission approves Glivec label update

Chinese institute divulges new beta-secretase 1 inhibitors

Esmya approved in Europe

Scripps Research Institute receives funds to develop new HIV inhibitors

Sanofi discloses new platelet adhesion-inhibiting peptides

Galen acquires chemotherapy agent from Gilead

FDA approves protocol amendment to ARISER study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Molecular signatures show subtypes in neurodegenerative diseases
BioWorld Science
Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...
More than two to tango: multispecifics at ESMO TAT
BioWorld Science
Multispecifics took center stage at this year’s ESMO TAT, emerging as one of the hottest trends in oncology research. Unlike traditional small-molecule drugs or...